Form 4: Fortress Biotech Director Granted Restricted Stock

Fortress Biotech Director Kevin Lorenz received a grant of 27,322 restricted common shares under the company's 2013 Stock Incentive Plan.

Summary

• Fortress Biotech, Inc. Director Kevin Lorenz was granted 27,322 shares of common stock on January 1, 2026.
• The grant was made under the Issuer's 2013 Stock Incentive Plan, as amended, with a grant price of $0 per share.
• These restricted shares will vest in three equal annual installments, with one-third vesting on January 1, 2027, January 1, 2028, and January 1, 2029.
• Vesting is contingent upon Mr. Lorenz's continued service to the company.
• Following this transaction, Mr. Lorenz beneficially owns a total of 101,009 shares of Fortress Biotech common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a neutral to slightly positive event, as it aligns the director's interests with shareholders and is a standard form of compensation, indicating stability in governance.

Positives

• The grant of restricted stock aligns Director Kevin Lorenz's long-term interests with those of Fortress Biotech shareholders.
• This equity compensation serves as a retention mechanism, incentivizing Mr. Lorenz's continued service and commitment to the company's strategic goals.

Negatives

• The shares are restricted and do not provide immediate liquidity or cash value to the director until they vest.
• The multi-year vesting schedule ties the director's compensation to future service, which could be perceived as a constraint on personal financial flexibility.

Risks

• The vesting of the granted shares is subject to Kevin Lorenz's continued service to Fortress Biotech; if his service ceases before the vesting dates, the unvested shares could be forfeited.

Future Outlook

The vesting schedule for the restricted stock grant implies an expectation of continued service from Director Kevin Lorenz through at least January 1, 2029.

Industry Context

The grant of restricted stock to a director is a common practice in the biotechnology industry and broader corporate landscape, serving as a key component of executive and director compensation packages to align interests and promote long-term retention.

Comparison to Industry Standards

• Equity compensation, such as restricted stock grants, is a standard component of director remuneration across publicly traded companies, including those in the biotech sector.
• The vesting schedule over multiple years is typical for such grants, designed to incentivize long-term commitment and performance, consistent with practices observed at comparable companies.

Corporate Governance

Related Party Transactions

• The grant of restricted stock to Director Kevin Lorenz constitutes a related party transaction, which is a standard form of director compensation approved under the company's equity incentive plan.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, potentially fostering more strategic decision-making.
• Employees: No direct impact on general employees is indicated, but it reflects the company's approach to executive and director compensation.

Next Steps

• Vesting of one-third of the granted restricted shares on January 1, 2027, subject to continued service.
• Vesting of one-third of the granted restricted shares on January 1, 2028, subject to continued service.
• Vesting of the final one-third of the granted restricted shares on January 1, 2029, subject to continued service.

Key Dates

Keywords

Fortress Biotech, FBIO, Kevin Lorenz, Restricted Stock, Stock Grant, Director Compensation, SEC Form 4, Equity Incentive Plan, Insider Transaction